ENO2 and cutaneous melanoma: Our analysis of publicly available gene expression data is consistent with previous studies reporting upregulation of glycolytic enzymes GPI [105], ALDOA [106], GAPDH [107,108], PKM [108,109], LDHA [110,111], PGAM1 [112], and ENO1 [113], as well as downregulation of ALDOC [114], while it was first to discover upregulation of ENO2, PGK1, TPI1, PFKL, and HK3 and downregulation of ENO3 in skin melanoma patients.